Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA and High-Dose Flu Vaccine Co-administration Study
NCT05559476Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Oct 2022; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05559476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559476.